New Perspectives on the Risk of Secondary Cancers After CAR T-cell Therapy
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
Tag: CAR T-cell therapy
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
The AACR journal editors' picks for July 2024 include a review of the risks from CAR T-cell therapy, advances...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
As the spring weather encourages the planting of flowers, vegetables, and herbs, even careful gardeners may see weeds creeping...
For the sixth time since 2015, researchers, clinicians, drug developers, patient advocates, and other stakeholders convened at the International...
Immunotherapy has revolutionized cancer treatment over the past decade, providing potentially lifesaving therapies to many patients who otherwise would have limited options. Despite its success...
In 2012, Carl June, MD, a pioneer in the development of chimeric antigen receptor (CAR) T-cell therapy, helped treat Emily Whitehead, the...
“The field of cell therapy is one of the most exciting fields in translational medicine,” began Katayoun Rezvani, MD, PhD,...
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric...
One of the most watched areas in the immuno-oncology field is the development of chimeric antigen receptor (CAR) T-cell...